Abstract
To bring the notion of cardiac regenerative medicine to fruition, researchers have tried to determine which stem cells, embryonic stem (ES) cells or somatic stem cells, are most suitable. Thus far, there is no clear indication which is better, because both have their own advantages and disadvantages. In 2006, murine induced pluripotent stem (iPS) cells were first established. Since then, basic research into the properties of iPS cells has continued apace. Originally, human iPS cells were generated from dermal fibroblasts by retrovirus-mediated gene transfer. Although this technique is sophisticated and easy to perform, the skin biopsy is accompanied by some bleeding and pain, and there may be some damage to the host genome because of retrovirus-mediated transgene integration. However, methods of producing iPS cells have improved steadily. For clinical application in the cardiovascular field, efficient methods that produce pluripotent stem cells that can differentiate into cardiomyocytes need to be developed. Existing methods for ES cells can be applied to iPS cells to obtain cardiomyocyte differentiation. In addition, existing purification methods can be used to obtain pure cardiomyocytes from a population of mixed cells. These techniques have themselves been the subject of extensive research, and continued advances are now making the clinical application of pluripotent stem cells a reality. We are at the forefront of medical innovations in the cardiovascular field based on the use of pluripotent stem cells.
| Original language | English |
|---|---|
| Title of host publication | Emerging Trends in Cell and Gene Therapy |
| Publisher | Humana Press Inc. |
| Pages | 225-249 |
| Number of pages | 25 |
| ISBN (Print) | 9781627034173, 1627034161, 9781627034166 |
| DOIs | |
| Publication status | Published - 2013 Dec 1 |
Fingerprint
Keywords
- Cardiomyocyte
- Differentiation
- ES cells
- iPS cells
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Induced pluripotent stem cells : New advances in cardiac regenerative medicine. / Yuasa, Shinsuke; Murata, Mitsushige; Fukuda, Keiichi.
Emerging Trends in Cell and Gene Therapy. Humana Press Inc., 2013. p. 225-249.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Induced pluripotent stem cells
T2 - New advances in cardiac regenerative medicine
AU - Yuasa, Shinsuke
AU - Murata, Mitsushige
AU - Fukuda, Keiichi
PY - 2013/12/1
Y1 - 2013/12/1
N2 - To bring the notion of cardiac regenerative medicine to fruition, researchers have tried to determine which stem cells, embryonic stem (ES) cells or somatic stem cells, are most suitable. Thus far, there is no clear indication which is better, because both have their own advantages and disadvantages. In 2006, murine induced pluripotent stem (iPS) cells were first established. Since then, basic research into the properties of iPS cells has continued apace. Originally, human iPS cells were generated from dermal fibroblasts by retrovirus-mediated gene transfer. Although this technique is sophisticated and easy to perform, the skin biopsy is accompanied by some bleeding and pain, and there may be some damage to the host genome because of retrovirus-mediated transgene integration. However, methods of producing iPS cells have improved steadily. For clinical application in the cardiovascular field, efficient methods that produce pluripotent stem cells that can differentiate into cardiomyocytes need to be developed. Existing methods for ES cells can be applied to iPS cells to obtain cardiomyocyte differentiation. In addition, existing purification methods can be used to obtain pure cardiomyocytes from a population of mixed cells. These techniques have themselves been the subject of extensive research, and continued advances are now making the clinical application of pluripotent stem cells a reality. We are at the forefront of medical innovations in the cardiovascular field based on the use of pluripotent stem cells.
AB - To bring the notion of cardiac regenerative medicine to fruition, researchers have tried to determine which stem cells, embryonic stem (ES) cells or somatic stem cells, are most suitable. Thus far, there is no clear indication which is better, because both have their own advantages and disadvantages. In 2006, murine induced pluripotent stem (iPS) cells were first established. Since then, basic research into the properties of iPS cells has continued apace. Originally, human iPS cells were generated from dermal fibroblasts by retrovirus-mediated gene transfer. Although this technique is sophisticated and easy to perform, the skin biopsy is accompanied by some bleeding and pain, and there may be some damage to the host genome because of retrovirus-mediated transgene integration. However, methods of producing iPS cells have improved steadily. For clinical application in the cardiovascular field, efficient methods that produce pluripotent stem cells that can differentiate into cardiomyocytes need to be developed. Existing methods for ES cells can be applied to iPS cells to obtain cardiomyocyte differentiation. In addition, existing purification methods can be used to obtain pure cardiomyocytes from a population of mixed cells. These techniques have themselves been the subject of extensive research, and continued advances are now making the clinical application of pluripotent stem cells a reality. We are at the forefront of medical innovations in the cardiovascular field based on the use of pluripotent stem cells.
KW - Cardiomyocyte
KW - Differentiation
KW - ES cells
KW - iPS cells
UR - http://www.scopus.com/inward/record.url?scp=84929916877&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929916877&partnerID=8YFLogxK
U2 - 10.1007/978-1-62703-417-3_10
DO - 10.1007/978-1-62703-417-3_10
M3 - Chapter
AN - SCOPUS:84929916877
SN - 9781627034173
SN - 1627034161
SN - 9781627034166
SP - 225
EP - 249
BT - Emerging Trends in Cell and Gene Therapy
PB - Humana Press Inc.
ER -